Malmö, December 23, 2016
Coronary Artery Disease Specialist Acarix AB to present at Medtech Showcase 2017
Recent oversubscribed IPO provides funds for accelerated commercialization of CADScor®System
Acarix AB (ACARIX), a Swedish/Danish medical device company specializing in non-invasive, non radiation acoustic detection of Coronary Artery Disease (CAD), today announced that Søren Rysholt Christiansen, Chief Executive Officer, will be presenting at Medtech Showcase 2017 in San Francisco. This follows the company`s recent successful listing on Nasdaq First North Premier in Stockholm which raised SEK140 million which has attracted widespread interest among potential international collaborators.
The Acarix presentation will be part of Track B at Parc 55 Union Square on Tuesday, January 10, 2017 at 2:45 PM Pacific Time.
The CADScor®System fills a major gap in the Coronary Artery Disease diagnostic pathway by combining acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a handheld device to provide a patient specific CAD-Score in less than 10 minutes. CE-Marked, the CADScor®System is due for commercial launch in 2017, initially in selected European markets.
Søren Rysholt Christiansen commented: "Medtech Showcase provides an immediate opportunity for us to capitalize on the major interest generated by our recent successful IPO. We look forward to meeting with both potential US and international collaborators as we accelerate our commercial efforts to bring CADScor®System to market and thus help impact and improve Coronary Artery Disease diagnosis and management."
Søren Rysholt Christiansen, CEO
Phone: +45 2777 1112
Richard Hayhurst, Ola Bjorkman
Phone: +44 7711 821527
Notes to editors:
Acarix , CADScor®System and cardiac sound measurement
Acarix A/S was established in 2009, and since 2010 investors SEED Capital (DK) and Sunstone Life Science Ventures (DK) have supported it towards market introduction. Acarix has attracted a highly-experienced management team who have held senior positions in international medical device companies - CEO Søren Rysholt Christiansen with ELOS Medtech, GN ReSound and Cook Medical.
Acarix`s CADScor®System is based on engineering excellence in sound recording and signal processing. It has long been known that both cardiac contraction movement and turbulent flow can generate sound. Contraction related sounds are in lower frequency, whereas turbulent sounds in the streaming blood caused by partial obstruction (stenosis) in the coronary arteries are of higher frequencies. The detection of these murmurs is delicate, since the energy of the murmurs is very weak. Detecting and recording the coronary murmurs requires not only an advanced sensor but also means for proper attachment to the skin above the heart to optimize the recorded signal and to avoid external noise.
The Acarix CADScor®System has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed and displayed as a patient specific score, the CAD-score, on the device screen. The CADScor®System contains the necessary electronics to instruct professionals during use and guide the patient through the recording periods. The system also contains a docking station for daily qualification of the sensor. Further the system integrates with an adhesive patch for locking the CADScor® sensor to a fixed position above the heart during the recording.
The software embedded in The Acarix CADScor®System ensures that adequate recording conditions are controlled at every examination, whether performing your examinations in a quiet clinical settings or at busy GP clinics, at high altitudes (>95% coverage) or on the move.
The CADScor®System is CE Marked (by TÜV in 2015) and due for commercial launch in 2017.
See more at www.acarix.com
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acarix AB via GlobeNewswire